Definium Therapeutics, Inc. 8-K

What Happened

• Definium Therapeutics, Inc. announced on June 23, 2026 that it entered into an underwriting agreement for an underwritten public offering of 20,588,236 common shares at $34.00 per share. The underwriters’ 30-day option to purchase an additional 3,088,235 shares was exercised in full on June 24, 2026. The offering is expected to close on June 25, 2026.

Key Details

• Offering price: $34.00 per share.
• Shares offered: 20,588,236, with an additional 3,088,235-share option exercised (total up to 23,676,471 shares).
• Gross proceeds (with full option): ≈ $805 million; expected net proceeds: ≈ $758 million after fees and expenses.
• Use of proceeds: research & development of product candidates, preparation for potential commercialization of DT120 ODT (if approved), and working capital/general corporate purposes.
• Underwriters (representatives): J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and BofA Securities, Inc. Insider lock-up: company directors, executive officers and the company agreed not to sell shares without underwriters’ consent for 60 days, subject to exceptions.

Why It Matters

• The financing provides Definium with a substantial cash infusion (≈ $758M net) to fund R&D and commercialization preparations for DT120 ODT and other corporate needs.
• Issuing up to ~23.68 million new shares will increase the company’s outstanding share count, which dilutes existing shareholders’ ownership proportionally.
• The 60-day lock-up limits insider share sales in the short term, while the completed exercise of the underwriters’ option shows strong demand or stabilization terms for the deal.